Scientists believe a little girl born with HIV has been cured of the infection.
She's
the first child and only the second person in the world known to have
been cured since the virus touched off a global pandemic nearly 32 years
ago.
Doctors aren't releasing the child's name, but we know
she was born in Mississippi and is now 2 ½ years old – and healthy.
Scientists presented details of the case on Sunday at a
scientific conference in Atlanta.
The case has big implications. While
fewer than 130
such children are born each year in the U.S., an estimated 330,000
children around the world get infected with HIV at or around birth every
year, most of them in sub-Saharan Africa.
And while
many countries are striving to prevent these mother-to-child infections, many thousands of children will certainly get infected in coming years.
Until
now, such children have been considered permanently infected.
Specialists thought they needed lifelong antiviral drugs to prevent HIV
from destroying their immune system and killing them of AIDS.
The
Mississippi child's surprising cure came about from happenstance – and
the quick thinking of a University of Mississippi pediatric infectious
disease specialist named Hannah Gay.
"The child came to our
attention as a high-risk exposure to maternal HIV," Gay tells Shots. Her
mother hadn't had any prenatal care, she says, so didn't get antiviral
drugs during pregnancy.
The fact that the newborn tested
positive for HIV within 30 hours of birth is a sign she was probably
infected in utero, HIV specialists say.
Gay decided to begin
treating the child immediately, with the first dose of antivirals given
within 31 hours of birth. That's faster than most infants born with HIV
get treated, and specialists think it's one important factor in the
child's cure.
In addition, Gay gave higher-than-usual,
"therapeutic" doses of three powerful HIV drugs rather than the
"prophylactic" doses usually given in these circumstances.
Over
the months, the baby thrived and standard tests could detect no virus
in her blood, which is the normal result from antiviral treatment.
Then, her mother stopped bringing the child in for checkups.
"The
baby's mom was having some life changes, that's about all I can say,"
Gay reports. "I saw her at 18 months, and then after that did not see
her for several months. And we were unable to locate her for a while."
Gay
enlisted the help of Mississippi state health authorities to track down
the child. When they found her, the mother said she'd stopped giving
antiviral drugs six or seven months earlier.
At that point, Gay
expected to find that the child's blood was teeming with HIV. But to
her astonishment, tests couldn't find any virus.
"My first
thought was, 'Oh my goodness, I've been treating a child who's not
actually infected,' " Gay says. But a look at the earlier blood work
confirmed the child had been infected with HIV at birth. So Gay then
thought the lab must have made a mistake with the new blood samples. So
she ran those tests again.
"When all those came back negative, I knew something odd was afoot," Gay says. She contacted an old friend,
Dr. Katherine Luzuriaga at the University of Massachusetts, who has been studying pediatric HIV/AIDS for two decades.
That was last August. Since then, Luzuriaga's lab and those in
San Diego,
Baltimore and
Bethesda, Md., have run ultra-sensitive tests on the baby's blood.
A
couple of tests have intermittently found pieces of HIV DNA and RNA,
but no evidence that the virus is actively replicating in the child's
cells.
Luzuriaga tells Shots this amounts to what's called a "functional cure."
She says that "means control of viral replication and lack of rebound once they come off anti-retroviral medications."
The only other such case known to AIDS researchers is the so-called
Berlin patient
– a San Francisco man named Timothy Brown. But his treatment involved a
bone marrow transplant in Germany – essentially, he was given the
immune system of a donor who's genetically resistant to HIV. That's not
something that can be easily duplicated.
By contrast, the Mississippi child's cure involved readily available medications.
Luzuriaga
says researchers believe they have ruled out other possible reasons for
the unexpected cure. For instance, the mother did not have a less
virulent strain of HIV. And the child does not have known mutations in
her immunity genes that confer protection against HIV.
"We
think it was that very early and aggressive treatment," she says, "that
curtailed the formation of viral reservoirs" – that is, hideouts for the
virus within the child's immune cells.
Previous research indicates that once these hideouts are established, it can take
70 years or more of steady, three-drug antiviral treatment to eliminate them.
Luzuriaga says the toddler's cure has electrified researchers searching for an HIV cure.
"It's exciting to us," she says. "Because if we were able to replicate this, I think it would be very good news."
Dr.
Deborah Persaud of Johns Hopkins University Medical School, who
presented the case at the Congress on Retroviruses and Opportunistic
Infections, calls the Mississippi cure "definitely a game-changer."
"This case is sort of the inspiration and provides the rationale to really move forward," Persaud tells Shots.
Kevin
Robert Frost of the Foundation for AIDS Research, or amfAR, agrees that
the finding will stimulate a lot of further work. The group helped fund
studies to determine if the Mississippi toddler is really cured.
"If this approach is proven effective, we could dramatically change the way children born with HIV are treated," he tells Shots.
Plans
are under way to mount studies to see if early, aggressive treatment
can cure other children of HIV. But Persaud says it will be a while
before researchers can figure out when it might be safe to stop
antiviral drugs deliberately.
This research will undboubtedly
be high-priority, given the birth of nearly 1,000 HIV-infected newborns a
day in the developing world.
AIDS researchers foresee a day
when the same treatment could give many of these children a lifetime
free of toxic and costly antiviral drugs.